- Home
- DMAC vs DBL Comparison
DMAC vs DBL Comparison
Compare DMAC & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DBL
- Stock Information
- Founded
- DMAC 2000
- DBL 2011
- Country
- DMAC United States
- DBL United States
- Employees
- DMAC N/A
- DBL N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- DMAC Health Care
- DBL
- Exchange
- DMAC Nasdaq
- DBL Nasdaq
- Market Cap
- DMAC 310.1M
- DBL 291.3M
- IPO Year
- DMAC N/A
- DBL N/A
- Fundamental
- Price
- DMAC $6.96
- DBL $15.63
- Analyst Decision
- DMAC Strong Buy
- DBL
- Analyst Count
- DMAC 3
- DBL 0
- Target Price
- DMAC $12.33
- DBL N/A
- AVG Volume (30 Days)
- DMAC 343.5K
- DBL 61.0K
- Earning Date
- DMAC 11-12-2025
- DBL 01-01-0001
- Dividend Yield
- DMAC N/A
- DBL 8.67%
- EPS Growth
- DMAC N/A
- DBL N/A
- EPS
- DMAC N/A
- DBL N/A
- Revenue
- DMAC N/A
- DBL N/A
- Revenue This Year
- DMAC N/A
- DBL N/A
- Revenue Next Year
- DMAC N/A
- DBL N/A
- P/E Ratio
- DMAC N/A
- DBL N/A
- Revenue Growth
- DMAC N/A
- DBL N/A
- 52 Week Low
- DMAC $3.19
- DBL $13.75
- 52 Week High
- DMAC $7.49
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- DBL N/A
- Support Level
- DMAC $6.75
- DBL N/A
- Resistance Level
- DMAC $7.13
- DBL N/A
- Average True Range (ATR)
- DMAC 0.28
- DBL 0.00
- MACD
- DMAC -0.06
- DBL 0.00
- Stochastic Oscillator
- DMAC 50.00
- DBL 0.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.